Population Pharmacokinetic and Pharmacodynamic Modeling of AZD4901 and Simulation to Support Dose Selection for the Phase 2a Study.

about

Population Pharmacokinetic and Pharmacodynamic Modeling of AZD4901 and Simulation to Support Dose Selection for the Phase 2a Study.

Item

http://www.wikidata.org/entity/Q50906448

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh-hant

name

Population Pharmacokinetic and ...... ection for the Phase 2a Study.

@en

Population Pharmacokinetic and ...... ection for the Phase 2a Study.

@nl

type

Item

label

Population Pharmacokinetic and ...... ection for the Phase 2a Study.

@en

Population Pharmacokinetic and ...... ection for the Phase 2a Study.

@nl

prefLabel

Population Pharmacokinetic and ...... ection for the Phase 2a Study.

@en

Population Pharmacokinetic and ...... ection for the Phase 2a Study.

@nl

P1476

Population Pharmacokinetic and ...... ection for the Phase 2a Study.

@en

P2093

Hongmei Xu

http://www.w3.org/2001/XMLSchema#string

Jianguo Li

http://www.w3.org/2001/XMLSchema#string

Lorraine Webber

http://www.w3.org/2001/XMLSchema#string

Nidal Al-Huniti

http://www.w3.org/2001/XMLSchema#string

Rahul Kakkar

http://www.w3.org/2001/XMLSchema#string

Yingxue Chen

http://www.w3.org/2001/XMLSchema#string

P2860

The kisspeptin-GnRH pathway in human reproductive health and disease

Opinion: NK3 receptor antagonists: the next generation of antipsychotics?

Adverse effects of the common treatments for polycystic ovary syndrome: a systematic review and meta-analysis.

The selective neurokinin 3 antagonist AZD2624 does not improve symptoms or cognition in schizophrenia: a proof-of-principle study.

In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia.

The circadian variation in Anti-Müllerian hormone in patients with polycystic ovary syndrome differs significantly from normally ovulating women.

The effect of diurnal variation on clinical measurement of serum testosterone and other sex hormone levels in men

In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics.

Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men.

The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria.

P304

999-1008

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCPH.680

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-12-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26626581

http://www.w3.org/2001/XMLSchema#string

P921

pavinetant